Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in
treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most
widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been
FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used
off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is
less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month
randomized, prospective interventional trial comparing the effectiveness of ranibizumab with
bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change
in central retinal thickness. Secondary measures are change in visual acuity from baseline
and change in angiographic properties of macular lesions from baseline after treatment.
Phase:
N/A
Details
Lead Sponsor:
Barnes Retina Institute
Collaborators:
Illinois Retina Associates Kresge Eye Institute Long Island Vitreoretinal Consultants Massachusetts Eye and Ear Infirmary Mid Atlantic Retina Retina Associates of Florida, P.A. Retina Associates, Kansas City